Latest research on Rituxan

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

Rituxan dosage

She completed 4 weekly Rituxan doses and received weekly Soliris for 3 weeks, and her factor V levels normalized to 54% activity with undetectable inhibitor titers. [source, 2015]
In active HBV infection group, at the very beginning of the therapy time, 66.7% (14/21) patients could not receive MabThera, 57.1%(12/21) were forced to reduce the chemotherapy dose, 23.8%(5/21) avoided MabThera and reduced the chemotherapy dose, and 33.3% (7/21) patients received radiation therapy, all of these were blamed for HBV activation. [source, 2015]
It is possible that this result was influenced by the reduced chemotherapy dosage or the lack of MabThera treatment. [source, 2015]
Under combination treatment with Cyclophosphamide (13 cycles every six weeks, cumulative dosage of 8300mg/m2) followed by another cycle of Rituxan, our patient developed no further relapses over an observation period of 2.5 years. [source, 2014]
She received adjusted dose R-CHOP X6, followed by Rituxan X2. [source, 2013]
However, 1 year ago her CLL relapsed and three doses of Rituxan were administered. [source, 2013]
For example, MabThera is indicated for follicular non-Hodgkin lymphoma (NHL), diffuse large B cell lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis, with dosing ranging from 375 mg/m2 administered weekly to 1000 mg administered as two doses 14 days apart. [source, 2013]
He was initially treated with corticosteroids at a dose of 1 mg/kg and a cycle of rituximab (MabThera, Hoffmann-La Roche, Ltd.) given as 2 intravenous doses of 1 g two weeks apart. [source, 2012]
At this point the decision for the experimental use of AntiCD20 antibody-treatment was made and one single RTX dose was given. [source, 2009]
Promising preliminary data suggest efficacy of adding to MTX the drugs Temodar [33] and Rituxan [38]; the provision of autologous stem cell transplantation [39, 40] and low dose brain radiation. [source, 2009]